News >

Balancing Genomic and Clinical Risk in HR+ Breast Cancer

Caroline Seymour
Published: Tuesday, Sep 10, 2019

Nina D'Abreo, MD, medical director of the Breast Program at NYU Winthrop Hospital, clinical assistant professor, Department of Medicine, NYU Langone Health

Nina D'Abreo, MD

In order to effectively tailor therapy to women with early-stage, hormone receptor (HR)–positive, HER2-negative breast cancer, equal consideration of a patient’s genomic and clinical risk is required, explained Nina D’Abreo, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication